ProShare Advisors LLC Has $1.21 Million Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

ProShare Advisors LLC grew its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 30.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,594 shares of the company's stock after purchasing an additional 9,268 shares during the period. ProShare Advisors LLC's holdings in Guardant Health were worth $1,210,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. NewEdge Advisors LLC grew its holdings in Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after acquiring an additional 230 shares during the period. Summit Investment Advisors Inc. grew its position in Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock worth $377,000 after buying an additional 391 shares during the period. Arizona State Retirement System increased its holdings in Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after buying an additional 403 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after acquiring an additional 817 shares during the period. Finally, R Squared Ltd purchased a new stake in shares of Guardant Health during the 4th quarter worth approximately $26,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Price Performance

Shares of GH stock traded down $0.78 during trading hours on Wednesday, reaching $38.39. The stock had a trading volume of 345,249 shares, compared to its average volume of 2,136,826. The firm has a market capitalization of $4.76 billion, a PE ratio of -10.79 and a beta of 1.49. The firm has a 50-day simple moving average of $43.11 and a 200-day simple moving average of $40.30. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. During the same quarter in the previous year, the company posted ($0.46) earnings per share. The business's revenue for the quarter was up 20.8% compared to the same quarter last year. On average, equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Buying and Selling at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now directly owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. This trade represents a 4.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 107,132 shares of company stock valued at $5,248,393. Company insiders own 6.10% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on GH shares. Barclays boosted their target price on Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, May 1st. Mizuho began coverage on shares of Guardant Health in a research report on Thursday, April 10th. They set an "outperform" rating and a $55.00 target price for the company. TD Securities increased their price target on shares of Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Morgan Stanley lifted their price objective on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. Finally, Guggenheim reissued a "buy" rating and set a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Twenty-one investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $52.32.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.